TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16771779

Group type: EXPERIMENTAL
Intervention: Montelukast + Loratadine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 15541413

Group type: EXPERIMENTAL
Intervention: 3 mL of Gynol II gel
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 5 mL of Gynol II gel
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Simulated intercourse
Number of subjects: 10
Study: 11185653

Group type: EXPERIMENTAL
Intervention: Alcohol withdrawal (abstinence from alcohol for 4 weeks)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Alcohol consumption (mean 81.8 g/d, range 40-150 g/d)
Number of subjects: 236
Study: 9293612

Group type: EXPERIMENTAL
Intervention: Valaciclovir (1000 mg, twice daily)
Number of subjects: 643

Group type: COMPARATOR
Intervention: Acyclovir (200 mg, 5 times daily)
Number of subjects: 643
Study: 8420348

Group type: EXPERIMENTAL
Intervention: Pipelle device
Number of subjects: 25

Group type: COMPARATOR
Intervention: Vabra aspirator
Number of subjects: 25
Study: 3523662

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 31535829

Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg once daily)
Number of subjects: 4744

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4744
Study: 28478107

Group type: EXPERIMENTAL
Intervention: Individualized endobronchial photodynamic therapy (PDT) under fluorescence control, violet light 408nm, diagnostic light.
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard PDT procedure, 662nm, pulse‐periodic mode, therapeutic light (reference group).
Number of subjects: 90
Study: 26541878

Group type: EXPERIMENTAL
Intervention: Loperamide-simeticone caplet
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Loperamide-simeticone chewable tablet
Number of subjects: 415

Group type: COMPARATOR
Intervention: S. boulardii
Number of subjects: 415
Study: 23107580

Group type: EXPERIMENTAL
Intervention: Informative reminders by telephone or in person (Group 1)
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Free cataract surgery (Group 2)
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Free surgery and reimbursement of transportation expenses (Group 3)
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Free rides from home to hospital in addition to the reminder and free surgery (Group 4)
Number of subjects: 432

Group type: COMPARATOR
Intervention: Comparison between Group 2 and Group 3
Number of subjects: 432

Group type: COMPARATOR
Intervention: Comparison between Group 2 and Group 4
Number of subjects: 432
Study: 20928835

Group type: EXPERIMENTAL
Intervention: Oral zinc gluconate plus corticosteroid treatment
Number of subjects: 66

Group type: COMPARATOR
Intervention: Corticosteroid treatment
Number of subjects: 66
Study: 18602474

Group type: EXPERIMENTAL
Intervention: MK (1.0 mg morphine + 5 mg ketamine/bolus)
Number of subjects: 58

Group type: COMPARATOR
Intervention: MO (1.5 mg morphine/bolus)
Number of subjects: 58
Study: 17140533

Group type: EXPERIMENTAL
Intervention: ART group (excavated with hand instruments)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Conventional group (excavated with burs)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Carisolv group (excavation with a chemical solution and special blunt hand instruments)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Residual caries
Number of subjects: 217

Group type: COMPARATOR
Intervention: Cervical gaps
Number of subjects: 217

Group type: COMPARATOR
Intervention: Combination of residual caries and cervical gaps
Number of subjects: 217
Study: 14523778

Group type: EXPERIMENTAL
Intervention: Indinavir-based therapy (with or without other antiretroviral drugs)
Number of subjects: 371
Study: 10921143

Group type: EXPERIMENTAL
Intervention: Tong Luo Kai Bi Tablets
Number of subjects: 120

Group type: COMPARATOR
Intervention: Rheumatic Semen Strychni Tablets
Number of subjects: 120
Study: 7536475

Group type: EXPERIMENTAL
Intervention: Interferon (IFN-alpha 2b, including nine patients with additional IFN gamma)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Busulfan (BU)
Number of subjects: 49
Study: 1665177

Group type: EXPERIMENTAL
Intervention: Lisinopril-hydrochlorothiazide 20 mg and 12.5 mg (L/HCTZ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lisinopril 40 mg once daily (L40)
Number of subjects: 0
Study: 6821404

Group type: EXPERIMENTAL
Intervention: Intralipid 10% i.v.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no infusion)
Number of subjects: 20
Study: 30030330

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 100 U
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 26682721

Group type: EXPERIMENTAL
Intervention: Perineural dexamethasone 8 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone 8 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Perineural saline 0.9%
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intravenous saline 0.9%
Number of subjects: 90
Study: 24342681

Group type: EXPERIMENTAL
Intervention: MR(+)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: SM(+)
Number of subjects: 28

Group type: COMPARATOR
Intervention: MR(‐)/SM(+)
Number of subjects: 28
Study: 22389919

Group type: EXPERIMENTAL
Intervention: Ocrelizumab 200 mg
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Ocrelizumab 500 mg
Number of subjects: 840

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 840
Study: 20390409

Group type: EXPERIMENTAL
Intervention: Intramuscular clodronate at a dose of 100 mg weekly for 12 months
Number of subjects: 91

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 91
Study: 18709953

Group type: EXPERIMENTAL
Intervention: Dextran (Group A)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Viscoat (Group B)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control eyes of Group A
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control eyes of Group B
Number of subjects: 68
Study: 16108943

Group type: EXPERIMENTAL
Intervention: Albumin levels at 3 months post-discharge
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: 3-month post-discharge albumin levels
Number of subjects: 282
Study: 12418424

Group type: EXPERIMENTAL
Intervention: Nitrates administered orally and/or transdermally
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9659191

Group type: EXPERIMENTAL
Intervention: alpha tocopherol (vitamin E) 50 mg/day
Number of subjects: 1795

Group type: EXPERIMENTAL
Intervention: alpha tocopherol (vitamin E) 50 mg/day and beta carotene 20 mg/day
Number of subjects: 1795

Group type: EXPERIMENTAL
Intervention: beta carotene 20 mg/day
Number of subjects: 1795

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1795
Study: 8618789

Group type: EXPERIMENTAL
Intervention: Indomethacin (3 x 0.2 mg/kg/12 h)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Aspirin (4 x 15 mg/kg/6 h)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 75
Study: 2744182

Group type: EXPERIMENTAL
Intervention: Embryo transfer at 44 to 48 hours after insemination
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Embryo transfer at 68 to 72 hours after insemination
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Sequential embryo transfer at 44 to 48 and 68 to 72 hours after insemination
Number of subjects: 51
Study: 952335

Group type: EXPERIMENTAL
Intervention: Outpatient group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inpatient group
Number of subjects: 0
Study: 31397551

Group type: EXPERIMENTAL
Intervention: Active attentional bias modification (ABM) training for 14 days
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo training for 14 days
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Active attentional bias modification (ABM) training
Number of subjects: 134
Study: 30427231

Group type: EXPERIMENTAL
Intervention: PTPD‐12 moisturizer
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control moisturizer
Number of subjects: 43
Study: 28561184

Group type: EXPERIMENTAL
Intervention: Isocaloric diet (diet group, n=6)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Regular unrestricted diet (non‐diet group, n=6)
Number of subjects: 12
Study: 24602919

Group type: EXPERIMENTAL
Intervention: Left coronary dominance
Number of subjects: 1387

Group type: COMPARATOR
Intervention: Non-left dominance
Number of subjects: 1387
Study: 23403680

Group type: EXPERIMENTAL
Intervention: Tedizolid phosphate (200 mg once daily for 6 days)
Number of subjects: 667

Group type: COMPARATOR
Intervention: Linezolid (600 mg every 12 hours for 10 days)
Number of subjects: 667
Study: 21702678

Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer liner
Number of subjects: 48

Group type: COMPARATOR
Intervention: Flowable resin composite liners
Number of subjects: 48

Group type: COMPARATOR
Intervention: Two kinds of adhesive systems (Single Bond and Clearfil SE Bond)
Number of subjects: 48
Study: 20184056

Group type: EXPERIMENTAL
Intervention: Topical diltiazem hydrochloride ointment (2%)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Topical glyceryl trinitrate ointment (0.2%)
Number of subjects: 102
Study: 16702331

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation among HIV-1 infected participants
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: HIV-1 infection
Number of subjects: 600

Group type: COMPARATOR
Intervention: RBP:TTR cut-off value of 0.25
Number of subjects: 600

Group type: COMPARATOR
Intervention: Acute phase response
Number of subjects: 600
Study: 15651756

Group type: EXPERIMENTAL
Intervention: Twice-daily indinavir/ritonavir (800/100 mg) regimen
Number of subjects: 118

Group type: COMPARATOR
Intervention: Three-times-daily indinavir regimen
Number of subjects: 118
Study: 11234265

Group type: EXPERIMENTAL
Intervention: Atenolol (25 mg)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 71
Study: 9413804

Group type: EXPERIMENTAL
Intervention: Sodium valproate (SV) 400 mg
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Sodium valproate (SV) 800 mg
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 8549956

Group type: EXPERIMENTAL
Intervention: Prophylactic inspiratory muscle training (PIMT) using a threshold trainer for 30 min/day for 1 month before operation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham training (Control)
Number of subjects: 30
Study: 2612249

Group type: EXPERIMENTAL
Intervention: Responsive maternal play technique; trained mothers
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Positive mood induction
Number of subjects: 32

Group type: COMPARATOR
Intervention: Negative mood induction
Number of subjects: 32
Study: 12665

Group type: EXPERIMENTAL
Intervention: High-dose lorazepam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose lorazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amylobarbitone
Number of subjects: 0
Study: 30785704

Group type: EXPERIMENTAL
Intervention: Buccal graft
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Penile skin applied
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: End-to-end anastomosis
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Neutrophil, lymphocyte counts and neutrophil/lymphocyte ratio
Number of subjects: 117
Study: 28407184

Group type: EXPERIMENTAL
Intervention: Industrial tomato lines (CVR 1, CVR 3, CVR 4, CVR 5, CVR 21, CVR 22)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 25
Study: 25867149

Group type: EXPERIMENTAL
Intervention: Nebulized 5% hypertonic saline
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Mixed 5% hypertonic saline with epinephrine
Number of subjects: 94

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 94
Study: 22188047

Group type: EXPERIMENTAL
Intervention: Depression-focused interpersonal counseling (IPC)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 103
Study: 20069390

Group type: EXPERIMENTAL
Intervention: Increased serum cortisol levels
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Cortisol levels
Number of subjects: 31
Study: 18767579

Group type: EXPERIMENTAL
Intervention: Cranial needling plus medication
Number of subjects: 43

Group type: COMPARATOR
Intervention: Medication
Number of subjects: 43
Study: 15930445

Group type: EXPERIMENTAL
Intervention: Safflower preload (SAFF)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Walnut preload (WNT)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Walnut oil preload (WOL)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Low-fat control (LFC)
Number of subjects: 25
Study: 12880828

Group type: EXPERIMENTAL
Intervention: Nicotine (12 microg/kg body weight)
Number of subjects: 0
Study: 10233187

Group type: EXPERIMENTAL
Intervention: Tinidazole 500 mg (OCT)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Metronidazole 400 mg (OCM)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Both regimens (OCT and OCM)
Number of subjects: 120
Study: 7759660

Group type: EXPERIMENTAL
Intervention: Metyrapone and hydrocortisone (30 mg daily hydrocortisone)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 1693740

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 134

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCT)
Number of subjects: 134
Study: 84131

Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (low-energy diet without levodopa)
Number of subjects: 0
Study: 31774376

Group type: EXPERIMENTAL
Intervention: Natural foot-landing position
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Fore-foot landing position
Number of subjects: 13

Group type: COMPARATOR
Intervention: Flat-foot landing position
Number of subjects: 13
Study: 30377715

Group type: EXPERIMENTAL
Intervention: Tri-calcium phosphate (TCP) granule
Number of subjects: 54

Group type: COMPARATOR
Intervention: Allogenous bone chip
Number of subjects: 54
Study: 28862220

Group type: EXPERIMENTAL
Intervention: Prone position using belly board
Number of subjects: 22

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 22
Study: 25683704

Group type: EXPERIMENTAL
Intervention: Plant stanol esters (4 g)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (shake without plant stanol esters)
Number of subjects: 14
Study: 23963128

Group type: EXPERIMENTAL
Intervention: Direct supervision
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Immediately available supervision
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Distant supervision
Number of subjects: 53

Group type: COMPARATOR
Intervention: Unsupervised scenarios
Number of subjects: 53
Study: 21748500

Group type: EXPERIMENTAL
Intervention: Prophylactic hypervolemic therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observational studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hyperdynamic therapy
Number of subjects: 0
Study: 19522983

Group type: EXPERIMENTAL
Intervention: High-dose squalene (27 g/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low-dose squalene (13.5 g/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both doses of squalene
Number of subjects: 40
Study: 17521741

Group type: EXPERIMENTAL
Intervention: Adrenaline (epinephrine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15373863

Group type: EXPERIMENTAL
Intervention: Surgery (ventilation tubes - VTs), n = 32
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group, n = 36
Number of subjects: 68
Study: 11710709

Group type: EXPERIMENTAL
Intervention: Ginger extract (EV.EXT 77), administered twice daily for 6 weeks
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Ginger extract (EV.EXT 77)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261
Study: 9172913

Group type: COMPARATOR
Intervention: AAS (Acetylsalicylic Acid)
Number of subjects: 0
Study: 10150223

Group type: EXPERIMENTAL
Intervention: Pre-hospital beta-blocker treatment (intravenous injection of atenolol)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Pre-hospital placebo treatment
Number of subjects: 77
Study: 29614993

Group type: EXPERIMENTAL
Intervention: Resistance training and protein supplementation (TRAINPRO)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Resistance training (TRAIN)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Protein supplementation (PRO)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control stretching (STRETCH)
Number of subjects: 37
Study: 27478133

Group type: EXPERIMENTAL
Intervention: Participants resistant to decline in function (n=289)
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: Participants demonstrating resilience (n=137 of 239)
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: High self-efficacy and social support
Number of subjects: 594
Study: 24626120

Group type: EXPERIMENTAL
Intervention: Epinephrine (adrenaline)
Number of subjects: 0
Study: 23652522

Group type: EXPERIMENTAL
Intervention: Long-detection interval (30 of 40 intervals)
Number of subjects: 1902

Group type: COMPARATOR
Intervention: Standard-detection interval (18 of 24 intervals)
Number of subjects: 1902

Group type: EXPERIMENTAL
Intervention: Long-detection interval
Number of subjects: 1902

Group type: COMPARATOR
Intervention: Standard-detection interval
Number of subjects: 1902
Study: 20006459

Group type: EXPERIMENTAL
Intervention: Patient navigation services
Number of subjects: 35

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 35
Study: 18795673

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (2500cGy/5 fractions)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no preoperative radiotherapy)
Number of subjects: 150
Study: 16922907

Group type: EXPERIMENTAL
Intervention: Recruitment into the trial
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Reasons for non-entry
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Preference for surgery/surgeon
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Lack of time
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Hospital accreditation issues
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Staffing/equipment issues
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Concern about doctor-patient relationship
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Anxiety caused to patients
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Availability of a data manager
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Increased caseload
Number of subjects: 113
Study: 12791627

Group type: EXPERIMENTAL
Intervention: 240 mL orange juice fortified with 1000 IU vitamin D(3) daily for 12 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control orange juice (not fortified)
Number of subjects: 18
Study: 10815856

Group type: EXPERIMENTAL
Intervention: Flashlamp‐pumped pulsed dye laser (FPDL) therapy for superficial hemangiomas
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Flashlamp‐pumped pulsed dye laser (FPDL) therapy for mixed hemangiomas
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Flashlamp‐pumped pulsed dye laser (FPDL) therapy for superficial hemangiomas in involution phase
Number of subjects: 165
Study: 8970899

Group type: EXPERIMENTAL
Intervention: 1.2 g/day of oral calcium as carbonate
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study: 1460161

Group type: EXPERIMENTAL
Intervention: Preparatory videotape (11-min duration)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control group (waiting period before appointment)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Prepared group (viewed videotape)
Number of subjects: 138
Study: 6698657

Group type: EXPERIMENTAL
Intervention: Acarbose (100 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 30293544

Group type: EXPERIMENTAL
Intervention: Virtual Reality Simulation (VRS) training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Web-based Clinical Updates (CU)
Number of subjects: 0
Study: 30286768

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (50,000 IU every other week for 8 weeks)
Number of subjects: 40
Study: 26780938

Group type: EXPERIMENTAL
Intervention: Immediate discontinuation group (IDG)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Tapered group (TG)
Number of subjects: 50
Study: 24650219

Group type: EXPERIMENTAL
Intervention: Daily 20 g lipid-based multi-micronutrient (MMN) supplement; additional 300 kcal/d for women with BMI <20 or low gestational weight gain
Number of subjects: 192

Group type: COMPARATOR
Intervention: None (Control group)
Number of subjects: 192
Study: 22436129

Group type: EXPERIMENTAL
Intervention: Febuxostat 80 mg
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Febuxostat 40 mg
Number of subjects: 374

Group type: COMPARATOR
Intervention: Allopurinol 200/300 mg
Number of subjects: 374
Study: 19460658

Group type: EXPERIMENTAL
Intervention: Family Healthware tool used directly after the baseline survey
Number of subjects: 3786

Group type: COMPARATOR
Intervention: Control group used the Family Healthware tool after completing the follow-up survey
Number of subjects: 3786
Study: 17495810

Group type: EXPERIMENTAL
Intervention: Demineralized bone transplant as osteoplastic material
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcium hydroxyapatite preparations
Number of subjects: 0
Study: 14962813

Group type: EXPERIMENTAL
Intervention: raloxifene (60 or 120 mg/day)
Number of subjects: 7705

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 7705
Study: 11591882

Group type: EXPERIMENTAL
Intervention: Glycerol ingestion (1 g glycerol in 20 ml H2O x kg(‐1) body weight)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (20 ml H2O x kg(‐1) body weight)
Number of subjects: 6
Study: 9870010

Group type: EXPERIMENTAL
Intervention: DDDR programming
Number of subjects: 407

Group type: COMPARATOR
Intervention: VVIR programming
Number of subjects: 407
Study: 7991650

Group type: EXPERIMENTAL
Intervention: Manipulation program with flexion and extension exercises (hand-heel rocks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Extension program
Number of subjects: 24